Literature DB >> 33030583

Targeting MALAT1 induces DNA damage and sensitize non-small cell lung cancer cells to cisplatin by repressing BRCA1.

Jinghua Huang1, Changxiu Lin2, Hai Dong3, Zhengri Piao1, Chunhua Jin4, Hengmin Han5, Dongchun Jin6.   

Abstract

PURPOSE: Metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) is a long non-coding RNA which has been identified to be involved in alternative non-homologous end joining (A-NHEJ) pathways by binding with PARP1 and LIG3 in myeloma cells. This study aims to explore the roles of MALAT1 in DNA repair processes in non-small cell lung cancer (NSCLC).
METHODS: The interactions between MALAT1 and proteins were identified by co-immunoprecipitation and RNA pulldown. The interactions between MALAT1 and microRNAs (miRNA) were predicted by bioinformatics tools and confirmed by luciferase assay and RNA pulldown. The DNA damages were quantified by comet assay. The cell viability was examined by MTT assay and the cell apoptosis was determined by flow cytometry.
RESULTS: MALAT1 is identified to be involved in A-NHEJ pathway in NSCLC cells. However, in LIG3-null cells where A-NHEJ pathway is inactivated, targeting MALAT1 still increases DNA damages, suggesting that MALAT1 participates in other DNA repair pathways. Subsequently, MALAT1 is identified to bind with miR-146a and miR-216b, which directly target the 3'UTR of BRCA1. MALAT1 is confirmed to functions as a competing endogenous RNA (ceRNA) absorbing miR-146a and miR-216b, upregulating BRCA1 expression and protecting Homologous Recombination (HR) pathway in NSCLC cells. Finally, overexpression MALAT1 protects NSCLC cells from the cytotoxic effect of cisplatin. While, targeting MALAT1 in NSCLC cells induces DNA damages by repressing HR pathway and sensitizes NSCLC cells to cisplatin which had the potential for NSCLC treatment.
CONCLUSION: MALAT1 is involved in HR pathway by protecting BRCA1 and targeting MALAT1 induces DNA damages in NSCLC.

Entities:  

Keywords:  DNA repair; Long non-coding RNA; MALAT1; Non-small cell lung cancer; microRNA

Mesh:

Substances:

Year:  2020        PMID: 33030583     DOI: 10.1007/s00280-020-04152-7

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  24 in total

1.  The Zn3 domain of human poly(ADP-ribose) polymerase-1 (PARP-1) functions in both DNA-dependent poly(ADP-ribose) synthesis activity and chromatin compaction.

Authors:  Marie-France Langelier; Donald D Ruhl; Jamie L Planck; W Lee Kraus; John M Pascal
Journal:  J Biol Chem       Date:  2010-04-13       Impact factor: 5.157

2.  Redundant function of DNA ligase 1 and 3 in alternative end-joining during immunoglobulin class switch recombination.

Authors:  Shahnaz Masani; Li Han; Katheryn Meek; Kefei Yu
Journal:  Proc Natl Acad Sci U S A       Date:  2016-01-19       Impact factor: 11.205

3.  Cancer statistics, 2015.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2015-01-05       Impact factor: 508.702

4.  MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer.

Authors:  Ping Ji; Sven Diederichs; Wenbing Wang; Sebastian Böing; Ralf Metzger; Paul M Schneider; Nicola Tidow; Burkhard Brandt; Horst Buerger; Etmar Bulk; Michael Thomas; Wolfgang E Berdel; Hubert Serve; Carsten Müller-Tidow
Journal:  Oncogene       Date:  2003-09-11       Impact factor: 9.867

Review 5.  Non-small-cell lung cancers: a heterogeneous set of diseases.

Authors:  Zhao Chen; Christine M Fillmore; Peter S Hammerman; Carla F Kim; Kwok-Kin Wong
Journal:  Nat Rev Cancer       Date:  2014-08       Impact factor: 60.716

6.  Circulating miR-19a and miR-205 in serum may predict the sensitivity of luminal A subtype of breast cancer patients to neoadjuvant chemotherapy with epirubicin plus paclitaxel.

Authors:  Qian Li; Mei Liu; Fei Ma; Yang Luo; Ruigang Cai; Liming Wang; Ningzhi Xu; Binghe Xu
Journal:  PLoS One       Date:  2014-08-19       Impact factor: 3.240

7.  LncRNA MALAT1 Depressed Chemo-Sensitivity of NSCLC Cells through Directly Functioning on miR-197-3p/p120 Catenin Axis.

Authors:  Tian Yang; Hong Li; Tianjun Chen; Hui Ren; Puyu Shi; Mingwei Chen
Journal:  Mol Cells       Date:  2019-02-19       Impact factor: 5.034

8.  YAP1-induced MALAT1 promotes epithelial-mesenchymal transition and angiogenesis by sponging miR-126-5p in colorectal cancer.

Authors:  Zhenqiang Sun; Chunlin Ou; Jinbo Liu; Chen Chen; Quanbo Zhou; Shuaixi Yang; Guiyuan Li; Guixian Wang; Junmin Song; Zhen Li; Zhiyong Zhang; Weitang Yuan; Xiayu Li
Journal:  Oncogene       Date:  2018-12-10       Impact factor: 9.867

9.  OpenComet: an automated tool for comet assay image analysis.

Authors:  Benjamin M Gyori; Gireedhar Venkatachalam; P S Thiagarajan; David Hsu; Marie-Veronique Clement
Journal:  Redox Biol       Date:  2014-01-09       Impact factor: 11.799

10.  Targeting the MALAT1/PARP1/LIG3 complex induces DNA damage and apoptosis in multiple myeloma.

Authors:  Yi Hu; Jianhong Lin; Hua Fang; Jing Fang; Chen Li; Wei Chen; Shuang Liu; Sarah Ondrejka; Zihua Gong; Frederic Reu; Jaroslaw Maciejewski; Qing Yi; Jian-Jun Zhao
Journal:  Leukemia       Date:  2018-03-22       Impact factor: 11.528

View more
  4 in total

1.  TRIM44 promotes BRCA1 functions in HR repair to induce Cisplatin Chemoresistance in Lung Adenocarcinoma by Deubiquitinating FLNA.

Authors:  Shuai Zhang; Mengru Cao; Shi Yan; Yuechao Liu; Weina Fan; Yimeng Cui; Fanglin Tian; Ruixue Gu; Yaowen Cui; Yuning Zhan; Yuanyuan Sun; Ying Xing; Li Cai; Yang Song
Journal:  Int J Biol Sci       Date:  2022-04-18       Impact factor: 10.750

Review 2.  miRNA dysregulation is an emerging modulator of genomic instability.

Authors:  Ana P Ferragut Cardoso; Mayukh Banerjee; Alexandra N Nail; Angeliki Lykoudi; J Christopher States
Journal:  Semin Cancer Biol       Date:  2021-05-09       Impact factor: 15.707

3.  The expression of miRNA-216b is negatively correlated with 18F-FDG uptake in non-small cell lung cancer.

Authors:  Mingfei Zuo; Lan Yao; Lijuan Wen; Jianfei Shen; Na Zhang; Tian Bai; Qicheng Huang
Journal:  World J Surg Oncol       Date:  2021-09-01       Impact factor: 2.754

Review 4.  Targeting lncRNAs in programmed cell death as a therapeutic strategy for non-small cell lung cancer.

Authors:  Yanqin Luo; Jingyang Li; Peng Yu; Jiayi Sun; Yingfan Hu; Xianli Meng; Li Xiang
Journal:  Cell Death Discov       Date:  2022-04-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.